CAJ | 학술논문

子宫内膜癌（endometrial carcinoma）是女性生殖系统最常见的恶性肿瘤之一。传统治疗以手术为主，辅以放疗、激素治疗和化疗。以往化疗多用于晚期及复发子宫内膜癌患者的治疗，最近研究认为，对早期高危子宫内膜癌辅助化疗或化疗联合放疗可降低局部复发和远处转移病率。化疗的适应证、药物的选择及方案的制定都影响化疗疗效。新兴分子靶向治疗药物较传统化疗药物毒副作用弱，目前临床应用研究较少，价格昂贵，疗效不确切，临床尚未作为常规治疗方案。
자궁내막암（endometrial carcinoma）시녀성생식계통최상견적악성종류지일。전통치료이수술위주，보이방료、격소치료화화료。이왕화료다용우만기급복발자궁내막암환자적치료，최근연구인위，대조기고위자궁내막암보조화료혹화료연합방료가강저국부복발화원처전이병솔。화료적괄응증、약물적선택급방안적제정도영향화료료효。신흥분자파향치료약물교전통화료약물독부작용약，목전림상응용연구교소，개격앙귀，료효불학절，림상상미작위상규치료방안。
Endometrial carcinoma is the most common malignancy of the female genital tract. The traditional treatment of endometrial cancer is surgical excision supplemented by radiotherapy ,chemotherapy and hormone therapy. Chemotherapy were used for the treatment of advanced and recurrent cancer patients ,the recent studies concluded that adjuvant chemotherapy or chemotherapy combined with radiotherapy can reduce the rate of local recurrence and distant metastasis disease for the early high-risk endometrial cancer . Indications of chemotherapy , drug selection and chemotherapy regimens could affected the efficacy of chemotherapy. The side-effects of molecular targeted therapeutic drugs are weaker than chemotherapy drugs ,too expensive of the clinical application and efficacy are not plausible ,is not recommended as routine treatment.